Estimation of the value-based price of a blood test for Alzheimer's disease pathology in primary and specialty care in the U.S.

ABSTRACT:

Background

Blood tests for the pathology of Alzheimer's disease (AD) are emerging as alternative to amyloid PET scans and analysis of cerebrospinal fluid. (CSF). However, their economic value, which depends on test accuracy as well as effect on clinical decision-making, remains unclear.

Methods

We use a Markov model to estimate the value-based price of a blood test with sensitivity of 88 % and specificity of 89 %, if labeled for triage and confirmation of the AD pathology in primary and specialty care. The value-based price was defined as price of the test, at which overall diagnostic cost per true positive case of early-stage AD would equate that under standard of care (identification in primary care and referral to specialty care based on the results of a brief cognitive t

SUBMITTER: Mattke S 

PROVIDER: S-EPMC12321617 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature